Please try another search
Inhibitor Therapeutics, Inc., a pharmaceutical development company, develops and commercializes therapeutics for patients with certain cancers and non-cancerous proliferation disorders in the United States. The company engages in the development of therapies for prostate and lung cancer utilizing itraconazole; and conducted a positive Phase 2b clinical trial of SUBA-Itraconazole for the treatment of basal cell carcinoma nevus syndrome. It has license agreement with Johns Hopkins University. The company was formerly known as HedgePath Pharmaceuticals, Inc. and changed its name to Inhibitor Therapeutics, Inc. in August 2019. Inhibitor Therapeutics, Inc. was founded in 1992 and is based in Tampa, Florida. Inhibitor Therapeutics, Inc is a subsidiary of Mayne Pharma Ventures Pty Ltd.
Name | Age | Since | Title |
---|---|---|---|
Francis E. O'Donnell | 74 | 2022 | Founder, Executive Chairman & CEO |
Samuel P. Sears | 80 | 2022 | Independent Director |
Elizabeth M. Billingsley | - | 2023 | Chairperson of the Scientific Advisory Board |
Allison Vidimos | - | 2023 | Member of Scientific Advisory Board |
Ronald E. Osman | 77 | 2023 | Non-Independent Director |
Niraj Vasisht | 60 | 2022 | Independent Director |
Marc D. Brown | - | 2023 | Member of Scientific Advisory Board |
Sean R. Christensen | - | 2023 | Member of Scientific Advisory Board |
Michael Jerman | 40 | 2023 | Independent Director |
Michelle Yanez | 51 | 2023 | Director |
Ian Maher | - | 2023 | Member of Scientific Advisory Board |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review